‌

US Patent 9850228 Pyrazolyl quinoxaline kinase inhibitors

Patent 9850228 was granted and assigned to Astex Therapeutics Limited on December, 2017 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

0

Patent attributes

Patent Applicant

Astex Therapeutics Limited

0

Current Assignee

Astex Therapeutics Limited

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Gilbert Ebai Besong0

Tom Cornelis Hortense Govaerts0

Valerio Berdini0

Werner Constant Johan Embrechts0

Alexandra Papanikos0

Berthold Wroblowski0

Christopher Charles Frederick Hamlett0

Christopher Norbert Johnson0

...

Date of Patent

December 26, 2017

0

Patent Application Number

151410610

Date Filed

April 28, 2016

0

Patent Citations Received

US Patent 11918576 Combination of an FGFR inhibitor and a CMET inhibitor

0

US Patent 11684620 Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine

0

Patent Primary Examiner

Jeffrey S Lundgren

0

Patent abstract

The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 9850228 Pyrazolyl quinoxaline kinase inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.